We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaxo's (GSK) Rukobia Gets EU Nod for Multidrug-Resistant HIV
Read MoreHide Full Article
GlaxoSmithKline plc’s (GSK - Free Report) HIV subsidiary, ViiV Healthcare announced that European Commission has granted approval to Rukobia (fostemsavir) in combination with other antiretroviral (ARV) therapies to treat heavily treatment-experienced adult patients with multidrug-resistant HIV.
The approval of Rukobia 600mg extended-release tablets was based on data from the pivotal phase III BRIGHTE study, which evaluated the safety and efficacy of Rukobia, a first-in-class attachment inhibitor, in combination with an optimized background therapy (“OBT”) in the given patient population. Data from the study showed that 60% of heavily treatment-experienced adult patients who received Rukobia with an OBT achieved and maintained viral suppression at 96 weeks of treatment. Rukobia was approved in the United States in July last year.
Rukobia’s EU approval is the second important regulatory approval in the HIV segment of Glaxo this year. Last month, the FDA approved Cabenuva, a long-acting injectable regimen of Glaxo’s cabotegravir and J&J’s (JNJ - Free Report) Edurant (rilpivirine) for the treatment of HIV-1 infection in virologically suppressed adults. Cabenuva is also approved in Canada and EU. The long-acting regimen will reduce the frequency of treatment days from 365 to 12 per year, thereby removing the need to take daily oral pills. The FDA simultaneously approved Vocabria (cabotegravir oral tablets) for short-term HIV treatment in combination with rilpivirine tablets.
So far this year, Glaxo’s shares have declined 3.7% against the industry’s 1.1% increase.
Please note that Pfizer (PFE - Free Report) and Shionogi Limited own stakes in ViiV Healthcare.
HIV is a key therapeutic area for Glaxo with dolutegravir-based regimens in its portfolio. The dolutegravir franchise comprises two three-drug regimens, namely Triumeq and Tivicay and two two-drug regimens, Juluca and Dovato. While sales of the two-drug regimens are rising, Glaxo is seeing decline in sales of Triumeq and Tivicay due to the transition of patients from three-drug regimens to two-drug regimens.
Rising competitive pressure coupled with shift within its portfolio toward two-drug regimens is hurting sales of Glaxo’s HIV business. Sales rose only 1% at constant exchange rate in 2020.
Other key players in the HIV market are Gilead Sciences (GILD - Free Report) ,Merck and AbbVie.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Glaxo's (GSK) Rukobia Gets EU Nod for Multidrug-Resistant HIV
GlaxoSmithKline plc’s (GSK - Free Report) HIV subsidiary, ViiV Healthcare announced that European Commission has granted approval to Rukobia (fostemsavir) in combination with other antiretroviral (ARV) therapies to treat heavily treatment-experienced adult patients with multidrug-resistant HIV.
The approval of Rukobia 600mg extended-release tablets was based on data from the pivotal phase III BRIGHTE study, which evaluated the safety and efficacy of Rukobia, a first-in-class attachment inhibitor, in combination with an optimized background therapy (“OBT”) in the given patient population. Data from the study showed that 60% of heavily treatment-experienced adult patients who received Rukobia with an OBT achieved and maintained viral suppression at 96 weeks of treatment. Rukobia was approved in the United States in July last year.
Rukobia’s EU approval is the second important regulatory approval in the HIV segment of Glaxo this year. Last month, the FDA approved Cabenuva, a long-acting injectable regimen of Glaxo’s cabotegravir and J&J’s (JNJ - Free Report) Edurant (rilpivirine) for the treatment of HIV-1 infection in virologically suppressed adults. Cabenuva is also approved in Canada and EU. The long-acting regimen will reduce the frequency of treatment days from 365 to 12 per year, thereby removing the need to take daily oral pills. The FDA simultaneously approved Vocabria (cabotegravir oral tablets) for short-term HIV treatment in combination with rilpivirine tablets.
So far this year, Glaxo’s shares have declined 3.7% against the industry’s 1.1% increase.
Please note that Pfizer (PFE - Free Report) and Shionogi Limited own stakes in ViiV Healthcare.
HIV is a key therapeutic area for Glaxo with dolutegravir-based regimens in its portfolio. The dolutegravir franchise comprises two three-drug regimens, namely Triumeq and Tivicay and two two-drug regimens, Juluca and Dovato. While sales of the two-drug regimens are rising, Glaxo is seeing decline in sales of Triumeq and Tivicay due to the transition of patients from three-drug regimens to two-drug regimens.
Rising competitive pressure coupled with shift within its portfolio toward two-drug regimens is hurting sales of Glaxo’s HIV business. Sales rose only 1% at constant exchange rate in 2020.
Other key players in the HIV market are Gilead Sciences (GILD - Free Report) ,Merck and AbbVie.
Glaxo currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>